Yasukawa: Good afternoon, everyone. I'm Yasukawa as the President of Astellas Pharma. Thank you for taking time out of your busy schedule to participate in our first sustainability meeting today. Slide 2 is the cautionary statement. As usual, I would like to skip the reading out.
Support
Japan
03.4405.3160
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
2
First, I would like to explain about our VISION.
Today, there are some participants who are usually not participating in our meetings. There are many such participants. First, I would like to talk about our VISION. That is the upper concept in our Corporate Strategic Plan or CSP.
On the forefront of the healthcare change to turn innovative science into VALUE for patients, that is our
VISION.
We have evolved and developed each Strategic Goal while inheriting the basic strategies in CSP2018. We'll contribute to the sustainability of society by solving social issues through its business activities by creating innovative pharmaceutical products. In addition, the trust that Astellas has from society, through its business activities improve the sustainability of Astellas.
In CSP2021, on top of the Strategic Goals 1, 2, 3, we have set new strategic goals for deepening our engagement in sustainability. In today's meeting, I will explain Astellas' initiatives to engage in sustainability, including Strategic Goal 4 and Organizational Health Goals, which I was unable to fully explain in the meeting in May last year.
Support
Japan
03.4405.3160
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
3
This is the agenda for today.
First of all, I would like to explain Astellas' activities to improve access to health, which we will refer to as improving ATH.
Support
Japan
03.4405.3160
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Astellas Pharma Inc. published this content on 01 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2022 05:37:07 UTC.
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
ASTELLAS PHARMA INC. 
